Based on the evidence presented in this review, all eligible patients with Ph+ ALL in second remission, those who do not achieve a CMR after three months of frontline therapy and patients harboring high-risk biological anomalies such as IKZF1 should be advised to undergo allo-HSCT. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.